I have seen this before. I was a significant beneficiary of Seth Klarman's M.O. when he took out IDIX. The exact same thing happened there. He started to buy up the company, had a seat on the board and before you knew it, MRK gobbled them up.
Klarman walked away with one billion.
I suggest everyone here hang on tightly to you shares. Every share you sell is being gobbled up by Baupost.
He is playing for a buy out, Join him, don't fight him, you cannot win.
in cardiac fibrosis.
Also see editorial. The thumbs down guys can continue to give me more thumbs down, but the science of Gal 3 in multiple organ systems is becoming overwhelming.
Stay the course !
Klarman is buying up every share. So just hold on to your shares, don't look for a couple of pennies here and there. if you stick with it, you will be rewarded in due time with the buy out.
Huge article on how NAFLD is an independent risk factor for cardiac disease.
Find it on Yahoo.
This is big. It means, unrelated to cirrhosis and its complications, you are a set up for cardiac events with NASH.
This expands the patient pool for NASH drugs to 1/2 the population.
IF data are good, and that is a big IF, this company will be bought out by either Gilead or Merck in the next 3 years.
Preferably we will have a bidding war.
I predict the buyout price will be market cap of 2 - 2.5 billion.
Please remember this post
Psoriasis is a major problem, especially in the Pediatric population.
Drugs that work have side effects and many do not work long term.
This is a serendipity finding that can be HUGE
See article on Yahoo from UC at San Diego (note, same center where they recently interviewed Galt in San Diego newspaper), on Januvia failing in double blind trial for NASH
Note also that trial employed MR elastography for fibrosis measurement in that trial.
Totally preclinical and a sidelight to their main focus. However, it does indicate that their is interest in their technology in different fields.
This should give pause to the board bozo that calls this a sugar pill, but it won't.
You're so dumb, you don't even realize how dumb you are.
the medical literature on Galectins is increasing every day.
Today's article- Januvia doesn't work, Previously Actos didn't work....all this research came out of UC at San Diego Liver Center where GALT was profiled in a recent article.
As the competition drops off, GALT looks better and better.